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The cholesterol reducing drugs, statins, exhibit anti-tumor effects against cancer stem cells and various
cancer cell lines, exert potent additivity or synergy with existing chemotherapeutics in animal models of
cancer andmay reduce cancer incidence and cancer relatedmortality in humans.However, not all tumor cell
lines are sensitive to statins, and clinical trials have demonstrated mixed outcomes regarding statins as
anticancer agents. Here, we show that statin-induced reduction in intracellular cholesterol levels correlate
with the growth inhibition of cancer cell lines upon statin treatment. Moreover, statin sensitivity segregates
with abundant cytosolic vimentin expression and absent cell surface E-cadherin expression, a pattern
characteristic of mesenchymal-like cells. Exogenous expression of cell surface E-cadherin converts statin-
sensitive cells to a partially resistant state implying that statin resistance is in part dependent on the tumor
cells attaining an epithelial phenotype. As metastasizing tumor cells undergo epithelial to mesenchymal
transition during the initiation of themetastatic cascade, statin therapymay represent an effective approach
to targeting the cells most likely to disseminate.
R
epurposing existing drugs for new clinical applications is one of the safest and least resource-intensive
approaches to improve therapeutic options1,2. In this regard, the cholesterol lowering drugs, statins, have
been reported to reduce cancer incidence and cancer relatedmortality in patients3,4. Similarly, many in vitro
experiments have shown antitumor effects of statins against cancer stem cells5,6 and various cancer cell lines
through suppression of cell proliferation and/or induction of apoptosis7–9. Statins also exert potent additivity or
synergy with existing chemotherapeutics. For example, fluvastatin combined with trastuzumab (a monoclonal
antibody against ErbB2) provides potent synergistic cytotoxic effects in human breast cancer cell lines10.
Moreover, fluvastatin or simvastatin significantly inhibited mammary tumor growth in ErbB2-transformed
Neu transgenic mice11. However, not all tumor cell lines are sensitive to statins, and clinical trials have reported
mixed outcomes regarding statins as anticancer agents7–9.
Metabolic reprogramming is inherent to tumor growth, and transformed cells require increased energy and
metabolic precursors to build the tumor cell biomass12,13. In addition, the metabolite-induced alteration of
epigenetic and regulatory states is also integral to tumor progression14,15. Metabolic alteration of cholesterol
synthesis is one pathway that is linked to tumorigenesis, and some cancer stem cells and cell lines exhibit
increased cholesterol synthesis through the mevalonate pathway5,16. Statins exert their antitumor effect through
their interference with tumor metabolism by inhibiting the enzyme, HMG-CoA reductase (HMGCR) that
catalyzes the rate limiting step of the mevalonate/cholesterol synthesis pathway7–9 (Supplementary Fig. S1).
Statin inhibition of HMGCR decreases the levels of mevalonate and its downstream products, including choles-
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terol, dolichol, ubiquinone, and the isoprenoid intermediates gera-
nyl-geranyl pyrophosphate and farnesyl pyrophosphate (Supple-
mentary Fig. S1).
The metabolic state of tumor cells, however, is not uniform.
Cancer cell lines range from small, highly proliferative cells to large,
slowly proliferating mesenchymal-like cells, and the growth inhib-
itory activity of statins is more potent against the latter type17. Yet,
biomarkers that demarcate statin sensitive cancer cell lines have not
been truly discerned, hampering their rational development as an
adjuvant therapy.
Here, we show that statin-sensitive cancer cell lines exhibit
mesenchymal-like phenotypes, characterized by abundant cytosolic
vimentin and absent cell surface E-cadherin expression. In the pres-
ence of atorvastatin, these cell lines deplete their cholesterol, an effect
that is circumvented by the simultaneous addition of mevalonate to
the cell culture. Moreover, exogenous expression of cell surface E-
cadherin converts statin-sensitive cells to a partially resistant state
implying that statin resistance is in part dependent on intact E-cad-
herin signaling. As metastasizing tumor cells undergo epithelial to
mesenchymal transition (EMT) during the initiation of the meta-
static cascade from the primary tumor site18, statin co-therapy may
be an effective approach to reduce the metastatic competency of
primary tumors and the rate of metastasis formation.
Results
Variable growth inhibition of cancer cell lines in response to
atorvastatin treatment. Previous experiments have demonstrated
that statins, including atorvastatin (Lipitor), inhibit the growth of a
subset of the NCI-60 cancer cell lines, and if one statin inhibited the
proliferation of a given cell line, then the other statins also showed
similar half maximal inhibitory concentration (IC50) values19. To
confirm these results, we cultured two cell lines from each of seven
organ types obtained from the NCI-60 collection in standard growth
medium with 10 mM atorvastatin. We found that atorvastatin
affected the proliferation rates of these cancer cell lines diffe-
rentially: the proliferation of some cell lines were fully or partially
inhibited by atorvastatin while others were insensitive to it (Fig. 1).
The growth inhibition in these cell lines does not correlate with
increased levels of select apoptosis markers (data not shown), im-
plying that statin treatment induces growth arrest.
The addition of mevalonate, the product of the HMGCR-
catalyzed reaction (Supplementary Fig. S1), to the growth medium
circumvents the effects of HMGCR inhibition or siRNA downregu-
lation of HMGCR expression7, presumably by substituting for endo-
genous mevalonate. To examine whether atorvastatin exerts its
growth inhibitory effect through HMGCR inhibition, we added
mevalonate to atorvastatin-treated cells. We found that mevalonate
reversed the atorvastatin-induced growth inhibition of the ten cancer
cell lines that displayed full or partial sensitivity to atorvastatin
(Fig. 1; Supplementary Fig. S2) in a dose-dependentmanner (Supple-
mentary Fig. S3). These cell lines express HMGCR at comparable
levels (Supplementary Fig. S4), demonstrating that statin sensitivity
is not due to differential enzyme expression.
Atorvastatin sensitivity correlates with decreased cholesterol
levels in atorvastatin-treated cells. Atorvastatin inhibits the enzy-
matic activity of HMGCR, thus blocking the synthesis of mevalonate
and its downstream products that include cholesterol (Supple-
mentary Fig. S1). To directly test the relationship between
atorvastatin sensitivity and cholesterol levels, we measured the
cholesterol content of the cell lines in the presence or absence of
atorvastatin using Filipin III, a pentaene macrolide routinely used
to assess intracellular cholesterol levels20. Representative results are
shown in Figure 2 (the entire data set is shown in Supplementary Fig.
S5A–C). Atorvastatin treatment drastically reduced the levels of
intracellular cholesterol in atorvastatin sensitive cell lines when
compared to that of the control DMSO treatment (Fig. 2G–I). In
contrast, addition of the drug did not affect the levels of
intracellular cholesterol in atorvastatin resistant cell lines (Fig. 2A–
C). Cell lines with partial atorvastatin sensitivity displayed an
intermediate phenotype upon atorvastatin treatment (Fig. 2D–F).
Thus, the sensitivity of cell lines to atorvastatin-induced growth
inhibition inversely correlated with the intracellular cholesterol
levels following atorvastatin treatment.
To further confirm that atorvastatin reduces the cells’ cholesterol
level through HMGCR inhibition, we measured the cholesterol con-
tent in the two most atorvastatin-sensitive cell lines (HOP-92, PC-3)
24 hours after the atorvastatin treatment in the presence or absence
of mevalonate supplementation. As expected, we found that the
addition of mevalonate to the growth medium prevented the ator-
vastatin-induced depletion of cholesterol typically seen in atorvasta-
tin sensitive cell lines (Supplementary Fig. S6).
Total vimentin and E-cadherin expression are not suitable
markers for statin sensitivity. The differential sensitivity of tumor
cell lines to atorvastatin could be utilized for adjuvant cancer therapy
if highly sensitive biomarkers were identified. Our previous analysis
of the NCI-60 cancer cell lines indicated that cells with larger dia-
meters in culture aremore sensitive to statin treatment. Furthermore,
increased cell size in culture correlated with higher vimentin protein
expression, a standardmarker of mesenchymal cell lineage, while the
epithelial marker E-cadherin negatively correlated with increased
cell size17. As these two markers are routinely used in standard
immunohistochemistry of tumor biopsy specimens, we probed
their utility as biomarkers of atorvastatin sensitivity.
First, we performed Western blot analyses to determine the aver-
age vimentin and E-cadherin expression in the fourteen cell lines.We
found that several cell lines express vimentin with absent or mini-
mal E-cadherin expression while cell lines deficient in vimentin
expressed a medium to high level of E-cadherin (Fig. 3). Of note,
some cell lines expressed both vimentin and E-cadherin (Fig. 3);
however, they also exhibited highly variable atorvastatin sensitivity.
For example, the PC-3 and DU-145 prostate cancer cell lines express
both proteins at comparable levels (Fig. 3), yet their responses to
atorvastatin are completely opposite (Fig. 1). These data indicate that
the correlation between mesenchymal marker vimentin and epithe-
lial marker E-cadherin expression cannot be used as dependable
biomarker for predicting or identifying atorvastatin sensitive cancer
cells.
Cytoplasmic vimentin expression without concomitant mem-
brane E-cadherin expression is a potential biomarker for
atorvastatin sensitivity. While vimentin is a cytoplasmic protein,
E-cadherin can be found in different subcellular localizations within
tumor cells21,22. E-cadherin homodimerization at the cell membrane
provides survival signals whereas destabilized E-cadherin are inter-
nalized and fails to signal23. To uncover the potential differences in E-
cadherin localization in the fourteen cell lines, we performed double
immunostaining for vimentin and E-cadherin expression, and
imaged using immunofluorescence microscopy.
Based on the collected data, the fourteen cell lines were segregated
into one of three groups, each with different patterns of vimentin and
E-cadherin expression (Fig. 4). First, six cell lines without cell surface
E-cadherin expression but uniformly expressed cytoplasmic vimen-
tin were atorvastatin-sensitive (Fig. 4A–F). These sensitive cell lines
differed in their total E-cadherin content: HOP-92 and SK-MEL-5
cells showed discernible intracellular E-cadherin expression, whereas
E-cadherin expression was undetectable in the other four cell lines
(Supplementary Fig. S7).
In contrast, cell lines that displayed any cell membrane E-cadherin
expression were either fully or partially atorvastatin-resistant
(Fig. 4H–N), irrespective of their cytoplasmic vimentin expression.
The degree of vimentin and E-cadherin expression varied among the
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Figure 1 | Growth rate of atorvastatin treated NCI-60 cancer cell lines. Colon cancer (A. HCT-116 and B. KM-12), ovarian cancer (C. IGROV1 and D.
OVCAR3), breast cancer (E. HS-578T and F. T47D), lung cancer (G. HOP-92 and H. NCI-H322M), prostate cancer (I. PC-3 and J. DU-145), melanoma
(K. SK-MEL-5 and L.MDA-MB-435), and brain cancer (M. SF-295 andN. SF-539) cell lines from the NCI-60 cancer cell line collection were treated with
10 mMatorvastatin (purple line) or DMSO vehicle control (blue line), and cell proliferation was quantified at 2, 4, and 6 days by direct cell counting. Each
value represents the mean 6 standard deviation (SD) (n53 for each group). The data were analyzed using Student’s t-test. * P,0.05, ** P,0.01.
www.nature.com/scientificreports
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individual cell lines. For example, DU-145 cells display both cyto-
plasmic vimentin and heterogeneous cell membrane E-cadherin
expression (Fig. 4K, Supplementary Fig. S8), whereas OVCAR3 cells
are vimentin negative but exhibit both cell membrane and intracel-
lular E-cadherin localization (Fig. 4M, Supplementary Fig. S8).
Despite this difference, both cell lines are fully resistant to atorvas-
tatin (Fig. 1).
A similar variation exists among partially resistant cell lines. T47D
andHCT-116 cells are positive for cellmembrane and cytoplasmic E-
cadherin but are vimentin negative (Fig. 4H, I), whereas IGROV1 cell
line is comprised of at least two different cell types. A subset of
IGROV1 cells are vimentin negative and positive for cell membrane
E-cadherin while another subset of cells is positive for cytoplasmic
vimentin, and exhibit cell membrane and cytoplasmic E-cadherin
(Fig. 4J, Supplementary Fig. S9).The only exception is the HS-578T
breast cancer cell line that is only partially atorvastatin sensitive
(Fig. 1), even though it has similar vimentin and E-cadherin express-
ion pattern as that observed in atorvastatin-sensitive cell lines
(Fig. 4G, Supplementary Fig. S9).
These results suggest that cell membrane E-cadherin expression is
a marker of full or partial atorvastatin resistance, whereas uniform
vimentin expression without any cell membrane E-cadherin express-
ion largely correlates with atorvastatin sensitivity.
Forced expression of cell surface E-cadherin converts atorvastatin-
sensitive cells to a partially atorvastatin resistant state. Given the
observed correlation between atorvastatin-resistance and cell mem-
brane E-cadherin expression, we aimed to determine whether
exogenously expressed membrane E-cadherin would induce a
resistant state in a statin-sensitive cell line. To this end, we used
derivatives of a highly statin-sensitive MDA-MB-231 cell line,
which express either dsRED (a RFP variant) alone or dsRED and
cell surface E-cadherin (Ecad)24. The RFP and Ecad cell lines were
treated with log-dilutions of atorvastatin and their cell numbers were
determined 3 days after treatment by crystal violet staining. We
found that the half maximal inhibitory concentration of atorva-
statin (IC50) in MDA-MB-231 cells shifted from 1.16 mM to
4.3 mM when cell surface E-cadherin was expressed (Fig. 5A). A
representative image of RFP and Ecad cells treated with 3 mM
atorvastatin illustrates this shift (Fig. 5B,C). In contrast, a PC-3
cell line with high exogenous cytoplasmic E-cadherin expression
Figure 2 | Cholesterol content of atorvastatin treated NCI-60 cancer cell lines. Cell lines were treated with 10 mM atorvastatin or 0.1% DMSO for
24 hours. Intracellular cholesterol levels were determined by Filipin III staining. Results for (A–C) atorvastatin resistant (DU-145), (D–F) partially
sensitive (T47D), and (G–I) sensitive cell lines (HOP-92) are shown. The full data set for all fourteen NCI-60 cell lines is shown in Supplementary Figure
S5. (A, D, G) DMSO control; (B, E, H) 10 mM atorvastatin treated cells; (C, F, I) histogram of cholesterol levels normalized to the DMSO controls. Each
value represents the mean 6 SD (n53 for each group). The data were analyzed using Student’s t-test. ** P,0.01.
Figure 3 | E-cadherin and vimentin expression of NCI-60 cancer cell
lines. The expression levels of E-cadherin and vimentin in the indicated
fourteen NCI-60 cell lines were determined by western blotting. b-actin
expression was used as the loading control. Representative images from
three experiments are shown.
www.nature.com/scientificreports
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did not show the same development of resistance to atorvastatin
(Supplementary Fig. S10). These data suggest that forced cell sur-
face E-cadherin expression can confer partial statin resistance to
formerly statin-sensitive cancer cells.
Discussion
Tissue dysfunction and cachexia due to growing metastases is the
cause of death in most cancer patients. Conceptually, the formation
of cancer metastases follows a cascade of events18. Initially, a fraction
of cancer cells in the primary tumor undergo EMT18,25 allowing them
to detach and intravasate into the circulation. These circulating,
mesenchymal-like tumor cells then reach distant organs whose suc-
cessful colonization requires a subsequent extravasation and partial
reversion of the tumor cells’ phenotype bymesenchymal to epithelial
reverting transition (MErT)18,26. After colonization, a variable length
of dormancy ensues27,28 followed by outgrowth of these dormant
micrometastases that requires at least a partial return to EMT18.
The challenge for the treatment of clinically evident metastases
and silent micrometastases (which are likely asynchronous in indi-
vidual metastatic nodules) is that existing chemotherapeutic strat-
egies against them are not effective. Therefore, there is a dire need for
pharmacotherapy that can reduce the metastatic competency of
primary tumors by targeting primary tumor cells that undergo
EMT and adopt a mesenchymal-like state.
In this study, we show that statins are potential drugs for such a
therapeutic purpose.We demonstrate that atorvastatin sensitive can-
cer cell lines aremesenchymal-like with abundant cytosolic vimentin
and no cell surface E-cadherin expression (Fig. 4A–F). In the pres-
ence of atorvastatin, the cholesterol levels of these sensitive cell lines
were severely reduced, and this effect was circumvented by the sim-
ultaneous addition of mevalonate to the cell culture medium. While
abundant cytosolic vimentin and absent cell surface E-cadherin
expression appear to be apt biomarkers for determining atorvastatin
sensitivity, the HS-578T breast cancer cell line that display such a
profile (Fig. 4G) is only partially resistant to atorvastatin (Fig. 1E).
Excluding the HS-578T cell line, all partially or fully atorvastatin
resistant cell lines express some degree of cell surface E-cadherin
(Fig. 4H–N). Moreover, cell surface E-cadherin expression mediates
the statin resistance to some degree as observed by the partial statin
resistance that was induced by exogenous membrane E-cadherin
expression in the mesenchymalMDA-MB-231 cell line (Fig. 5) while
cytoplasmic E-cadherin expression in the mesenchymal PC-3 cell
line (Supplementary Fig. S10) was without effect. Other aspects con-
tributing to statin resistance may include differences in gene express-
ion, post-translational modifications, compensatory upregulation of
HMGCR after statin therapy9, or enhanced export of statin from the
cells.
In statin-sensitive cell lines, the inhibition of HMGCR likely leads
to growth inhibition by at least three different mechanisms. First, a
mevalonate pathway-produced metabolite, geranyl-geranyl pyro-
phosphate inhibits Rho GTPases, which activate transcription fac-
tors YAP and TAZ of the Hippo pathway29–31 (Supplementary Fig.
S1). These transcription factors are not only crucial for normal organ
size control and stem cell renewal but also play an important role in
inducing tumorigenesis and metastasis29,32, in part by inducing
mesenchymal differentiation33, cancer stem cell related traits34, and
cancer cell motility30. Therefore, statin inhibition of HMGCR may
arrest cancer cell proliferation by inactivating downstream transcrip-
tion factors. Second, statins impair the glucose uptake of tumor
cells35. This effect is potentially related to the decreased cholesterol
concentration in the cell membrane, which is crucial for membrane
lipid raft functions that govern the subcellular localization and func-
tion of glucose transporters35 and other receptor complexes36. Third,
accumulation ofmetabolic precursors, such as acetyl CoA, could also
block glucose uptake through feedback inhibition of the glycolysis
pathway37.
Future studies will aim at examining the vimentin and E-cadherin
expression and functional state of circulating tumors cells.
Furthermore, the susceptibility of these tumor cells to statin treat-
ment will be explored using both in vitro cell cultures and an all-
humanmicrophysiological system that can recapitulate the early and
later stages of micrometastasis formation38. The molecular mode of
statin-sensitivity will also be discerned to determine if the key targets
are prenylation as opposed to cholesterol deficiency. Finally, statin-
drug combination therapies targeting downstream molecules of the
mevalonate pathway will be tested as a means to potentiate the sens-
Figure 4 | E-cadherin and vimentin expression and subcellular localization. Merged images of the NCI-60 cell lines immunostained for E-cadherin
(green, membrane, cytoplasmic or nuclear), vimentin (red, cytoplasmic), and Hoechst 33342 (blue, nucleus). A: PC-3, B: HOP-92, C: SK-MEL-5, D:
MDA-MB-435, E: SF-295, F: SF-539, G: HS-578T, H: T47D, I: HCT-116, J: IGROV1, K: DU-145, L: NCI-H322M,M: OVCAR3, and N: KM-12 cell lines.
Cell lines are labeled as atorvastatin-sensitive (A–F), -partially sensitive (G–J) or -resistant (K–N) based on the results of cell proliferation studies shown in
Figure 1.
www.nature.com/scientificreports
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itivity of partially sensitive mesenchymal-like tumor cells, and to
reduce the therapeutic dose of statins to a suitable level for routine
clinical use in oncology.
Methods
Cell cultures.We have selected 7 pairs of cell lines from the NCI-60 cancer cell panel
representing 7 different major solid tumor types. For each site we selected a cell line
with low and one with high protein synthesis rate, as previously reported17. (The
selection was performed prior to the vimentin and E-cadherin profiling for
mesenchymal and epithelial phenotype). The selected cell lines—colon cancer (HCT-
116 and KM-12), ovarian cancer (IGROV1 and OVCAR3), breast cancer (HS-578T
and T47D), lung cancer (HOP-92 and NCI-H322M), prostate cancer (PC-3 and DU-
145), melanoma (SK-MEL-5 and MDA-MB-435), and brain cancer (SF-295 and SF-
539)—were cultured in RPMI 1640 medium (Life Technologies, Grand Island, NY),
supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS, Life
Technologies) and 1% penicillin/streptomycin (Life Technologies) at 37uC with 5%
CO2.
Atorvastatin treatment and cell proliferation assay. Atorvastatin (Sigma-Aldrich,
St. Louis, MO) at a final concentration of 10 mMwas dissolved in dimethyl sulfoxide
(DMSO, Sigma-Aldrich; final concentration of 0.1% in RPMI 1640 medium). The
cells were seeded in 6-well plates at a density of 1 3 105 cells/ml and incubated
overnight prior to treating with 10 mMatorvastatin or 0.1%DMSO, which served as a
control. Three independent experiments were performed. Cell proliferation was
quantified at 2, 4, and 6 days by direct cell counting with ScepterTM Handheld
Automated Cell Counter (EMD Millipore, Billerica, MA) using ScepterTM Tips-
60 mm sensor (EMD Millipore), or by crystal violet staining. Preliminary studies
demonstrated that the two methods yielded congruent results.
Mevalonic acid treatment in atorvastatin sensitive cells. To determine whether
mevalonic acid treatment reverted the atorvastatin-sensitive phenotype, the cell lines
whose proliferation was inhibited by atorvastatin were seeded in 6-well plates at a
density of 1 3 105 cells/ml, incubated overnight, and then treated with 10 mM
atorvastatin and various concentrations (25 mM, 50 mM, 100 mM, and 200 mM) of R-
mevalonic acid (Sigma-Aldrich) for 24 hours. These cells were also photographed
with a phase-contrast microscope to capture any morphological changes.
Cholesterol staining. Subconfluent (40–60% confluency) cells grown on coverslips in
a 24-well plate were incubated with RPMI 1640medium supplemented with 10%HI-
FBS and 10 mMatorvastatin. To increase the visibility of the synthesized cholesterols,
a cholesterol intercellular trafficking inhibitor, U18666A (Cayman Chemical, Ann
Arbor, MI) was added to the culture medium at a concentration of 1.25 mM. Some of
the atorvastatin sensitive cells (HOP-92 and PC-3) were also treated with 100 mMR-
mevalonic acid (Sigma-Aldrich). Cells treated with 0.1% DMSO and 1.25 mM
U18666A served as control. After 24-hours incubation, the cells were stained using
the cholesterol cell-based detection assay kit (Cayman Chemical) according to the
manufacturer’s instructions. Briefly, the cells were fixed with 4% formaldehyde in
Tris-buffered saline (TBS) for 10 min and then washed in TBS with 0.1% Tween 20
(TBS-T). The cells were incubated with 50 mg/ml Filipin III in TBS, a probe used for
the fluorescent detection of sterols (excitation/emission, 340–380/385–470 nm).
After 1 hour incubation with Filipin III in the dark at room temperature (RT), the
cells were washed in TBS-T, followed by detachment and mounting of the coverslips
in the aqueous-based mounting medium (ClearmountTM, Invitrogen, Carlsbad, CA).
Images were taken under an Olympus Provis fluorescence microscope (Olympus
Optical, Tokyo, Japan) equipped with a 40X oil objective lens. Quantification of the
cholesterol levels was accomplished using the Granularity algorithm in the
MetaXpress image analysis software (Molecular Devices Corp., Sunnyvale CA). The
total integrated granule intensity was measured for each image and the percent
cholesterol remaining after atorvastatin treatment was calculated as the ratio of
granule intensity in the atorvastatin cells to that of the DMSO treated cells.
Western blotting. After removing spent media and washing cells with cold
phosphate buffered saline (PBS), the cells were incubated with cold Pierce RIPA lysis
buffer (Thermo Scientific, Hudson, NH) containing HaltTM Protease Inhibitor Single-
Use Cocktail, HaltTM Phosphatase Inhibitor Single-Use Cocktail (Thermo Scientific)
and 1 mM dithiothreitol (DTT) for 15 min with occasional swirling. Then, the cells
were scraped, homogenizedwith a 26-gauge needle and vortexed at the highest setting
for 1 min; the lysates were cleared by centrifuging at 16,000 g at 4uC for 15 min.
Protein concentration was determined with the bicinchoninic acid (BCA) method
(BCA Protein Assay - Reducing Agent Compatible; Thermo Scientific). Proteins were
separated on NuPAGE 4–12% Bis Tris gel electrophoresis (Life Technologies), and
transferred to a nitrocellulose membrane (iBlot Gel Transfer Stacks Nitrocellulose;
Life Technologies) using iBlot Gel Transfer Device (Life Technologies). The
membrane was probed with monoclonal rabbit antibodies, anti-HMGCR (15500,
ab174830, Abcam Inc., Cambridge, MA), anti-vimentin (151000, ab92547, Abcam),
Figure 5 | Effect of forced cell surface E-cadherin expression on atorvastatin sensitivity. (A)MDA-MB-231 RFP (.) orMDA-MB-231 RFP E-cadherin
(m) cells were treated with 0.1 mM, 0.3 mM, 1 mM, 3 mM, 10 mM, or 30 mM atorvastatin. Cell viability was assessed by crystal violet staining 3 days after
atorvastatin treatment and normalized to the 0.3% DMSO control. The data were fit with a sigmoid function to extrapolate the IC50 value (lines).
Each value represents the mean 6 SD (n53 for each group). The data for each MDA-MB-231 RFP E-cadherin cells were compared with those for the
controls (MDA-MB-231 RFP cells). Asterisk, two-way ANOVA (P,0.01) followed by t-test (P,0.05). (B) MDA-MB-231 RFP and (C) MDA-MB-231
RFP E-cadherin cells were treated with 3 mM atorvastatin. Imaging was done with 40X oil objective lens 3 days after the treatment.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 7593 | DOI: 10.1038/srep07593 6
and anti-E-cadherin (151000, 24E10, Cell Signaling Technology, Beverly, MA). A
monoclonalmouse antibody tob-actin (15500, ab8226, Abcam)was used as a loading
control. Immunodetection was performed using the iBlot Western Detection
chromogenic kit (Life Technologies).
Immunofluorescence microscopy. Cultured cells grown on coverslips in a 24-well
plate were fixed with 2% paraformaldehyde (Sigma-Aldrich) for 30 min, washed in
PBS, and then permeabilized with 0.1% Triton-X-100 (Fisher Scientific, Pittsburgh,
PA) made in PBS for 15 min. Following a PBS wash, non-specific proteins were
blocked in 2% BSA for 15 min at RT. The cells were incubated with a mixture of two
primary antibodies: monoclonal rabbit antibody to vimentin (15100, ab92547,
Abcam) and monoclonal mouse antibody to E-cadherin (1550, ab1416, Abcam) in a
humidified atmosphere for 1 hour at 37uC. Coverslips were then probed with Alexa
Fluor 488 goat anti-mouse IgG andAlexa Fluor 555 goat anti-rabbit IgG (both; 15200,
Abcam) in the dark for 15 min at RT. Following a PBS wash, nuclei were stained with
Hoechst 33342 (50 mg/ml) for 5 min at RT, washed and mounted in an aqueous-
based mounting medium ClearmountTM (Invitrogen). Images were captured with the
40X oil objective lens on the Olympus Provis fluorescence microscope (Olympus
Optical).
IC50 determination. MDA-MB-231 (breast cancer) and PC-3 (prostate cancer) cell
lines were seeded in 12-well plates at a concentration of 1 3 105 cells/ml. The next
day, cells were treated with 0.1 mM, 0.3 mM, 1 mM, 3 mM, 10 mM, or 30 mM
atorvastatin. Cells treated with 0.3% DMSO (the concentration of DMSO in the
30 mM atorvastatin treatment condition) served as a control group. Three days after
treatment, the cells were washed with PBS and fixed in 4% formaldehyde (F79-1,
Fisher Scientific) for 15 minutes. The cells were washed with milli-Q water and
stained with 0.5% w/v crystal violet (Sigma-Aldrich) for 10 minutes, and excess dye
was washed extensively with tap water. The absorbed dye was released with 2% SDS.
The supernatants were mixed thoroughly before transferring to a 96-well plate to be
read at 560 nm using a Tecan SpectraFluor microplate reader (Tecan US, Durham,
NC). IC50 values were determined by fitting a standard, four-parameter sigmoid curve
to the data. All treatments were carried out in triplicate samples.
Statistical analyses. Statistical analyses were performed using the StatView software
(version 5.0; SAS Institute Inc., Cary, NC). The data for atorvastatin-treated cells and
non-treated controls were compared using two-way analysis of variance (ANOVA)
and Student’s t-test. P-values less than 0.05 were regarded statistically significant.
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